The RANTES Chemokine: A New Target for Immunomodulatory Therapy?

James M. Pattison; Peter J. Nelson; Alan M. Krensky

doi:10.1007/BF03259067

The RANTES Chemokine: A New Target for Immunomodulatory Therapy?

James M. Pattison, Peter J. Nelson, Alan M. Krensky^*

^*Corresponding author for this work

Office of Finance and Administration

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

RANTES is a member of the C-C family of chemoattractant cytokines (chemokines). It is secreted by T lymphocytes late after activation, and by fibroblasts, epithelial cells and endothelial cells after stimulation with tumour necrosis factor-α, interleukin-1β and interferon-γ. RANTES is a potent chemoattractant for monocytes, memory T cells, basophils and eosinophils. It also triggers basophil degranulation and activates eosinophils. RANTES is highly expressed in acute cell-mediated transplant rejection, in chronic inflammatory diseases such as sarcoidosis and atherosclerosis, and by some malignancies. This novel cytokine may play a pivotal role in the recruitment of the mononuclear cell infiltrate present in these conditions, and represents a potential target for new therapeutic agents.

Original language	English (US)
Pages (from-to)	1-8
Number of pages	8
Journal	Clinical Immunotherapeutics
Volume	4
Issue number	1
DOIs	https://doi.org/10.1007/BF03259067
State	Published - Jul 1995

ASJC Scopus subject areas

Immunology and Allergy
Pharmacology (medical)

Access to Document

10.1007/BF03259067

Cite this

@article{38f1029812954e16945e7d470d36ce9d,

title = "The RANTES Chemokine: A New Target for Immunomodulatory Therapy?",

abstract = "RANTES is a member of the C-C family of chemoattractant cytokines (chemokines). It is secreted by T lymphocytes late after activation, and by fibroblasts, epithelial cells and endothelial cells after stimulation with tumour necrosis factor-α, interleukin-1β and interferon-γ. RANTES is a potent chemoattractant for monocytes, memory T cells, basophils and eosinophils. It also triggers basophil degranulation and activates eosinophils. RANTES is highly expressed in acute cell-mediated transplant rejection, in chronic inflammatory diseases such as sarcoidosis and atherosclerosis, and by some malignancies. This novel cytokine may play a pivotal role in the recruitment of the mononuclear cell infiltrate present in these conditions, and represents a potential target for new therapeutic agents.",

author = "Pattison, {James M.} and Nelson, {Peter J.} and Krensky, {Alan M.}",

year = "1995",

month = jul,

doi = "10.1007/BF03259067",

language = "English (US)",

volume = "4",

pages = "1--8",

journal = "Clinical Immunotherapeutics",

issn = "1172-7039",

publisher = "Adis International Ltd",

number = "1",

}

TY - JOUR

T1 - The RANTES Chemokine

T2 - A New Target for Immunomodulatory Therapy?

AU - Pattison, James M.

AU - Nelson, Peter J.

AU - Krensky, Alan M.

PY - 1995/7

Y1 - 1995/7

N2 - RANTES is a member of the C-C family of chemoattractant cytokines (chemokines). It is secreted by T lymphocytes late after activation, and by fibroblasts, epithelial cells and endothelial cells after stimulation with tumour necrosis factor-α, interleukin-1β and interferon-γ. RANTES is a potent chemoattractant for monocytes, memory T cells, basophils and eosinophils. It also triggers basophil degranulation and activates eosinophils. RANTES is highly expressed in acute cell-mediated transplant rejection, in chronic inflammatory diseases such as sarcoidosis and atherosclerosis, and by some malignancies. This novel cytokine may play a pivotal role in the recruitment of the mononuclear cell infiltrate present in these conditions, and represents a potential target for new therapeutic agents.

AB - RANTES is a member of the C-C family of chemoattractant cytokines (chemokines). It is secreted by T lymphocytes late after activation, and by fibroblasts, epithelial cells and endothelial cells after stimulation with tumour necrosis factor-α, interleukin-1β and interferon-γ. RANTES is a potent chemoattractant for monocytes, memory T cells, basophils and eosinophils. It also triggers basophil degranulation and activates eosinophils. RANTES is highly expressed in acute cell-mediated transplant rejection, in chronic inflammatory diseases such as sarcoidosis and atherosclerosis, and by some malignancies. This novel cytokine may play a pivotal role in the recruitment of the mononuclear cell infiltrate present in these conditions, and represents a potential target for new therapeutic agents.

UR - http://www.scopus.com/inward/record.url?scp=0029006307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029006307&partnerID=8YFLogxK

U2 - 10.1007/BF03259067

DO - 10.1007/BF03259067

M3 - Article

AN - SCOPUS:0029006307

SN - 1172-7039

VL - 4

SP - 1

EP - 8

JO - Clinical Immunotherapeutics

JF - Clinical Immunotherapeutics

IS - 1

ER -

The RANTES Chemokine: A New Target for Immunomodulatory Therapy?

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this